Table 2:

Clinical trials integrating and investigating incorporating PET imaging into the response assessment during IO therapy or the surveillance period following IO therapy for melanoma patients as registered at www.clinicaltrials.gov at the time of submission.

Study ID	Brief description	Country enrolling
		patients
NCT03356470	Comparing FDG PET and FLT PET, along with blood and tissue biomarkers	USA
NCT03888950	Evaluate whether FDG PET predicts therapeutic response after 2 cycles of PD-1 directed therapy	France
NCT04272658	Determine the value of 4D body-to-whole dynamic acquisition in FDG PET for immunotherapy monitoring	France
NCT03584334	Using FDG PET to distinguish tumor progression versus pseudo-progression in patients with melanoma or non-small cell lung cancer	France
NCT02716077	Early evaluation of response to pembrolizumab in patients with melanoma	USA
NCT04478318	Determine the minimum FDG PET scan duration on a total-body versus conventional scanner	USA
NCT04462406	Determine how FDG PET may allow early discontinuation of PD-1 directed therapy in unresectable stage IIIB-IV melanoma	USA
NCT03116412	Prospective randomized multicenter trial to assess the role of imaging during follow up after resection of Stage IIb-c and III melanoma	Sweden
NCT03554083	Determine the role of FDG PET in assessing response to neoadjuvant combination targeted and immunotherapy for patients with high-risk stage III melanoma	USA
NCT02621021	Determine the role of FDG PET in assessing response to talimogene laherparepvec with or without radiation for patients with advanced melanoma, Merkel cell carcinoma or other solid tumors with skin metastasis	USA
NCT02575404	Determine the role of FDG PET in assessing response to GR-MD-02 plus pembrolizumab for patients with advanced melanoma, nonsmall cell lung cancer or head and neck squamous cell cancer	USA
NCT04165967	Determine the role of FDG PET in assessing response to adoptive tumor infiltrating lymphocyte transfer plus nivolumab for patients with metastatic melanoma that failed immunotherapy	Switzerland
NCT03311308	Correlate hypoxia measurements in tumor via FDG PET in advanced melanoma patients treated with pembrolizumab with or without metformin	USA
NCT03161756	Determine the role of FDG PET in assessing response to denosumab plus nivolumab with or without ipilimumab for patients with	Australia
	metastatic melanoma
NCT04207086	Determine the role of FDG PET in assessing response to neoadjuvant pembrolizumab plus levatinib for patients with resectable stage III/IV melanoma	Australia
NCT03475134	Determine the role of FDG PET and 68GaNODAGA-RGD PET in assessing response to tumor infiltrating lymphocyte therapy plus nivolumab rescue for patients with unresectable locally advanced or metastatic melanoma	Switzerland
NCT02858921	Determine the role of FDG PET in assessing response to neoadjuvant dabrafenib, trametinib, and/or pembrolizumab for patients with BRAF mutant resectable stage III melanoma	Australia